Godavari Biorefineries Q3 FY26 Results: Revenue Up 2.5%, PBT Jumps 152%
Godavari Biorefineries reported Q3 FY26 revenue of ₹461.9 crore, up 2.5% YoY. PBT surged 152.3% to ₹21.4 crore due to reduced finance costs. The bio-based chemicals segment saw revenue grow 3.8% with improved margins. A new grain/maize distillery is set for Q1 FY27 commissioning, adding 60 million liters ethanol capacity.
The results show improved profitability and growth in core segments, alongside strategic investments in future capacity and new technology. This indicates a moderate positive impact on the company's financial health and market position.
The company reported positive financial results with revenue growth, significant PBT increase, and margin improvements in key segments. Strategic initiatives and future capacity expansions also contribute to a positive outlook.
Godavari Biorefineries Limited announced its financial results for the third quarter (Q3) and nine months (9M) of FY26. The company reported a consolidated revenue growth of 2.5% year-on-year (YoY) to ₹461.9 crore in Q3 FY26. EBITDA improved by 13.8% YoY to ₹45.1 crore, supported by approximately 100 basis points margin expansion.
Profit Before Tax (PBT) saw a significant increase of 152.3% YoY to ₹21.4 crore in Q3 FY26, primarily driven by a 46% reduction in finance costs. This reduction was largely due to the repayment of ₹240 crore term debt using IPO proceeds. The company's bio-based chemicals segment revenue grew by 3.8% YoY to ₹142.3 crore, with EBITDA improving by 76.7% and margins expanding by 317 basis points to 7.7% in Q3 FY26, driven by a higher contribution from specialty chemicals.
The ethanol segment, however, experienced a revenue decline of 23.6% YoY to ₹132.3 crore in Q3 FY26, with EBITDA contracting by 56.6%. This was partially offset by an increase in revenue and EBITDA for the 9M FY26 period, attributed to the availability of B-heavy molasses ethanol. The Sugar & Co-Generation segment showed robust growth with a 36.1% YoY increase in revenue to ₹180.9 crore in Q3 FY26.
For the 9M FY26 period, consolidated revenue stood at ₹1,430.2 crore, a 10.2% YoY increase. EBITDA for 9M FY26 was ₹47.2 crore, a significant improvement from a loss of ₹1.4 crore in the previous year. PBT for 9M FY26 was ₹(31.2) crore, compared to ₹(97.3) crore in 9M FY25.
Key strategic initiatives include the progress of the CO2-to-DME technology pilot project with ICT Mumbai and the incorporation of Sathgen Therapeutics LLC in the United States for its cancer drug IP. The company also highlighted the growth of its consumer brand 'Jivana', which reached ₹100 crore in revenue for 9M FY26 and is expanding its distribution network. A 200 KLPD fungible Grain/Maize distillery is planned for commissioning in Q1 FY27, which will add 60 million liters of ethanol capacity per annum.
What to do with a filing like this
Godavari Biorefineries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Godavari Biorefineries Limited. Read the original for the full detail.